Gainor [14] and Griesinger [22] pointed out that Pralsetinib had 79% and 74% ORR in KIF5B-RET positive NSCLC patients and 67% and 85% ORR in CCDC6-RET positive NSCLC patients, respectively. This evidence concerns the gene RET and non-small cell lung carcinoma.